Oglesby A, et al. Patient-reported outcomes after switching to a two-drug regimen of dolutegravir + rilpivirine: Week 100 results from the SWORD-1 and SWORD-2 studies. Abstract P101. HIV/Drug Therapy Glasgow 2018.
AQ-13 veelbelovend medicijn tegen resistente ‘Plasmodium falciparum’
sep 2017 | Parasitaire infecties